NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
LYNPARZA (olaparib) by AstraZeneca is poly(adp-ribose) polymerase inhibitors [moa]. First approved in 2017.
Drug data last refreshed 38m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYNPARZA (olaparib) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor approved in 2017 for oncology indications. It works by inhibiting PARP enzymes, which repair DNA damage, leading to cell death in BRCA-mutated and homologous recombination-deficient tumors. The drug is indicated across multiple cancer types and represents a foundational precision oncology asset.
Peak15.0 years to LOE
Peak lifecycle positioning indicates mature commercial infrastructure with established field teams; career growth opportunities center on line extension and indication expansion rather than launch scaling.
Mechanism of Action
Poly(ADP-Ribose) Polymerase Inhibitors
Pharmacologic Class:
Poly(ADP-Ribose) Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
PROLONG (PRostateOLaparibONcombinationGcc) Study
Started Jun 2026
75 enrolled
Metastatic Castration-resistant Prostate Cancer (mCRPC)
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
Started Jun 2026
35 enrolled
Ovary Cancer
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
Started Dec 2025
50 enrolled
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance
Started Sep 2025
50 enrolled
Endometrial Cancer
Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Started Aug 2025
33 enrolled
High Grade Serous Ovarian Cancer
Worked on LYNPARZA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.